Back

Quality of Anticoagulation Control and Major Adverse Outcomes in European Patients with Atrial Fibrillation: Analysis from EORP-AF General Long-Term Registry

19 March 2019 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster session 3 - Atrial Fibrillation - Stroke Prevention Oral Anticoagulation EHRA Premium Access EHRA 2019

About the speaker

Photo
Associate Professor Marco Proietti

University of Milan, Milan (Italy)

8 More presentations in this session

Presentation thumbnail
Associate Professor M. Proietti (Milan, IT)
Abstract Slides
Presentation thumbnail
Doctor B. Slavchev (Sofia, BG)
Abstract Slides
Presentation thumbnail
Doctor A. Bodin (Chambray Les Tours, FR)
Abstract
Presentation thumbnail
Doctor C. Tomasi (Ravenna, IT)
Abstract
Presentation thumbnail
Professor J. Camm (London, GB)
Abstract

Access the full session

Session thumbnail
Poster session 3 - Atrial Fibrillation - Stroke Prevention

The Event

Event poster

EHRA 2019

19 March 2019 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Association between thromboembolic and bleeding risk with adverse outcomes in contemporary European atrial fibrillation patients: final analysis from the ESC-EHRA EORP AF general long-term registry
23 April 2021
thumbnail
Congress Presentation
Adherence and treatment satisfaction among atrial fibrillation patients treated with VKAs versus NOACs: real-world data from a single-center cohort
12 April 2026
thumbnail
Congress Presentation
Generalizability of the EAST-AFNET 4 trial: assessing outcomes of early rhythm-control therapy in patients with atrial fibrillation
27 August 2021
thumbnail
Congress Presentation
One-year outcomes of inappropriate DOAC dosing in patients with atrial fibrillation
21 March 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources